![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 29, 2020 5:39:12 PM
The study was supposed to be 470 patients.they signed up 503.
The independent data monitoring committee recommended adding 210 patients. They already have 33 extra so they would have to add 177 more. This was a non binding recommendation. The company rejected this recommendation.
Does this mean that they don’t have enough money or that they don’t want to take the extra time or do they just think that patients signed up during Covid will not do as well?
Tonix “remains blinded to the interim results.” They plan to continue the study with the 503 patients and report results in 4th quarter 2020 which starts in 2 days.
They believe they have a winner for fibromyalgia. I am an MD and I can tell you that these patients are very difficult to treat. Many get addicted to opiates and kill themselves either accidentally or on purpose. Cymbalta is an antidepressant that causes weight gain and erectile dysfunction. Your pain gets better but you become obese and can’t have sex.
Lyrica and Neurontin cause sedation and don’t really help as much as opiates.
I think Seth knows he has a winner and wants to get his drug on the market ASAP
Recent TNXP News
- Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/28/2024 08:05:00 PM
- Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering • GlobeNewswire Inc. • 06/27/2024 12:36:51 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/26/2024 08:40:16 PM
- Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 06/26/2024 07:13:29 PM
- Tonix Pharmaceuticals Presents Vaccine Platform Data in Keynote Talk at the Vaccine Congress 2024 • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:05:23 PM
- Tonix Pharmaceuticals Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya™ for the Management of Fibromyalgia • GlobeNewswire Inc. • 06/20/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Data Comparing Real-World Treatment of Migraine with Industry Guidelines for Non-Oral Products at the Annual Scientific Meeting of the American Headache Society (AHS) • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Tonix Pharmaceuticals Presented Poster of Tonmya™ for the Management of Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/17/2024 12:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 09:25:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 09:24:27 PM
- Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/13/2024 09:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/12/2024 09:01:03 PM
- Tonix Pharmaceuticals Announces Pricing of $4.0 Million Public Offering • GlobeNewswire Inc. • 06/12/2024 01:00:00 PM
- Tonix Pharmaceuticals Announces Proposed Public Offering • GlobeNewswire Inc. • 06/11/2024 09:17:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/11/2024 08:49:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 12:53:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 03:21:23 PM
- Tonix Pharmaceuticals Announces 1-for-32 Reverse Stock Split • GlobeNewswire Inc. • 06/06/2024 03:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:05:39 PM
- Tonix Pharmaceuticals Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 (Fc-modified humanized anti-CD40L mAb) at the American Transplant Congress 2024 • GlobeNewswire Inc. • 06/06/2024 12:00:00 PM
- Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2024 • GlobeNewswire Inc. • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:05:27 PM
- Tonix Pharmaceuticals Presented New Data on Tonmya™ Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM